Another article about TH1902 and immunotherapy https://www.frontiersin.org/articles/10.3389/fimmu.2024.1355945
"This is the first evidence that TH1902 exerts its antitumor activity, in part, through modulation of the immune tumor microenvironment and that the combination of TH1902 with checkpoint inhibitors (anti-PD-L1) could lead to improved clinical outcomes."
Another preclinical study released today confirming the TH1902 combo therapy with immunotherapy will have better efficacy results.
It seems there research is progressively exploring the combo therapy recently.